Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not bee...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/7/1409 |
| _version_ | 1797212794790084608 |
|---|---|
| author | Atsuto Mouri Satoshi Watanabe Takaaki Tokito Yoshiaki Nagai Yu Saida Hisao Imai Ou Yamaguchi Kunihiko Kobayashi Kyoichi Kaira Hiroshi Kagamu |
| author_facet | Atsuto Mouri Satoshi Watanabe Takaaki Tokito Yoshiaki Nagai Yu Saida Hisao Imai Ou Yamaguchi Kunihiko Kobayashi Kyoichi Kaira Hiroshi Kagamu |
| author_sort | Atsuto Mouri |
| collection | DOAJ |
| description | Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not been determined. Between January 2021 and June 2022, clinical data were retrospectively extracted from the medical records of patients with NSCLC who received nivolumab plus ipilimumab after CCRT and durvalumab consolidation. A total of 30 patients were included in this analysis. The median number of durvalumab treatment cycles was 11. Median PFS and OS with nivolumab plus ipilimumab were 4.2 months (95% confidence interval [CI]: 0.7–7.7) and 18.5 months (95% CI: 3.5–33.5), respectively. The 6-month and 12-month PFS rates were 46.7% (95% CI: 28.8–64.5) and 36.4% (95% CI: 19.0–53.7). In multivariate analysis, a significant correlation was observed between a durvalumab treatment duration of 6 months or more and PFS (<i>p</i> = 0.04) as well as OS (<i>p</i> = 0.001). Grade 3 adverse events, including pneumonitis, dermatitis, and colitis, occurred in 10% of the patients. This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT. |
| first_indexed | 2024-04-24T10:48:03Z |
| format | Article |
| id | doaj.art-a1dd98b83cd04202929d5213660b4788 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-04-24T10:48:03Z |
| publishDate | 2024-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a1dd98b83cd04202929d5213660b47882024-04-12T13:16:17ZengMDPI AGCancers2072-66942024-04-01167140910.3390/cancers16071409Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by DurvalumabAtsuto Mouri0Satoshi Watanabe1Takaaki Tokito2Yoshiaki Nagai3Yu Saida4Hisao Imai5Ou Yamaguchi6Kunihiko Kobayashi7Kyoichi Kaira8Hiroshi Kagamu9Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, Saitama 330-0834, JapanDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka 350-1298, JapanNivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not been determined. Between January 2021 and June 2022, clinical data were retrospectively extracted from the medical records of patients with NSCLC who received nivolumab plus ipilimumab after CCRT and durvalumab consolidation. A total of 30 patients were included in this analysis. The median number of durvalumab treatment cycles was 11. Median PFS and OS with nivolumab plus ipilimumab were 4.2 months (95% confidence interval [CI]: 0.7–7.7) and 18.5 months (95% CI: 3.5–33.5), respectively. The 6-month and 12-month PFS rates were 46.7% (95% CI: 28.8–64.5) and 36.4% (95% CI: 19.0–53.7). In multivariate analysis, a significant correlation was observed between a durvalumab treatment duration of 6 months or more and PFS (<i>p</i> = 0.04) as well as OS (<i>p</i> = 0.001). Grade 3 adverse events, including pneumonitis, dermatitis, and colitis, occurred in 10% of the patients. This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT.https://www.mdpi.com/2072-6694/16/7/1409nivolumabipilimumabdurvalumabCCRTnon-small-cell lung cancer |
| spellingShingle | Atsuto Mouri Satoshi Watanabe Takaaki Tokito Yoshiaki Nagai Yu Saida Hisao Imai Ou Yamaguchi Kunihiko Kobayashi Kyoichi Kaira Hiroshi Kagamu Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab Cancers nivolumab ipilimumab durvalumab CCRT non-small-cell lung cancer |
| title | Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab |
| title_full | Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab |
| title_fullStr | Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab |
| title_full_unstemmed | Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab |
| title_short | Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab |
| title_sort | clinical outcome of nivolumab plus ipilimumab in patients with locally advanced non small cell lung cancer with relapse after concurrent chemoradiotherapy followed by durvalumab |
| topic | nivolumab ipilimumab durvalumab CCRT non-small-cell lung cancer |
| url | https://www.mdpi.com/2072-6694/16/7/1409 |
| work_keys_str_mv | AT atsutomouri clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT satoshiwatanabe clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT takaakitokito clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT yoshiakinagai clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT yusaida clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT hisaoimai clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT ouyamaguchi clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT kunihikokobayashi clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT kyoichikaira clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab AT hiroshikagamu clinicaloutcomeofnivolumabplusipilimumabinpatientswithlocallyadvancednonsmallcelllungcancerwithrelapseafterconcurrentchemoradiotherapyfollowedbydurvalumab |